Clinical Trials Search
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
The purposes of this study are to: Learn about the safety of BNZ132-1-40 (BNZ-1 for short) in participants with LGL or CTCL. Learn how participants tolerate BNZ-1. Find out how much BNZ-1 is in the participant's blood and for how long. Measure the ability of BNZ-1 to block the cytokine signals in the participant's body Determine if BNZ-1 helps fight the participant's cancer and produces any benefit to participants.
Primary Objective: The primary objective is to characterize the safety and tolerability of BNZ132-1-40 (BNZ-1) given intravenously (IV) once-weekly to patients with large granular lymphocyte leukemia (LGLL) or refractory cutaneous T-cell lymphoma (rCTCL). Secondary Objectives: The secondary objectives are: To characterize the preliminary clinical response to once-weekly BNZ-1 treatment in patients with LGLL or rCTCL. To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of once-weekly doses of BNZ-1 administered to patients with LGLL or rCTCL.